'Nab paclitaxel' presentation slideshows

nab-paclitaxel in combinazione Dati clinici e safety

831 views • 69 slides

Linda T. Vahdat, MD Medical Director, Breast Cancer Research Program Weill Cornell Medical College

Integration of Treatment Advances into Clinical Practice: Novel Microtubule-Targeting Agents in Metastatic Breast Cancer. Linda T. Vahdat, MD Medical Director, Breast Cancer Research Program Weill Cornell Medical College New York Presbyterian Hospital New York, NY. Program Goals.

923 views • 66 slides

Highlights of Metastatic Breast Cancer Research

Highlights of Metastatic Breast Cancer Research. ASCO 2007 : Highlights of Metastatic Breast Cancer Research. Single-Agent First-Line Therapy New data show improved clinical activity of nab -paclitaxel compared with docetaxel in patients with advanced breast cancer.

718 views • 50 slides

Clinical and pharmacological background

Clinical and pharmacological background. Microtubule stabilizing (and destabilizing) agents have relevant role in the treatment of breast cancer (and other tumors) They are natural compounds discovered serendipitously or in large-scale screens from plant, microbial, and marine sources

711 views • 40 slides

Nab-paclitaxel Development in Gynecologic Malignancies

Nab-paclitaxel Development in Gynecologic Malignancies. Robert Coleman, MD, FACOG, FACS Director of Clinical Research Department of Gynecologic Oncology MD Anderson Cancer Center. Nab-paclitaxel Gynecologic Malignancy Trials with Enrollment Complete.

430 views • 25 slides

Abstract #LBA7511

Abstract #LBA7511. Results of a Randomized, Phase III Trial of nab -Paclitaxel and Carboplatin Compared With Cremophor-based Paclitaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell Lung Cancer.

346 views • 22 slides

MEDICAL INTERNET NEWS

MEDICAL INTERNET NEWS. MEDIC 5 28/03/2019. Common acid reflux medications linked to increased kidney disease risk Date: February 19, 2019 Source: University of California - San Diego.

219 views • 21 slides

Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France

TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic Adenocarcinoma. MJ Borad, Mayo Clinic, Scottsdale, AZ et al. Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France. New drug, new concept, microenvironment.

329 views • 20 slides

Aggiornamenti scientifici di NAB-paclitaxel nel MBC in terapia di combinazione

298 views • 19 slides

CANCER PROGRAM

An update on clinical trials and personalised medicine for pancreas cancer in Australia Lorraine Chantrill Medical Oncologist Macarthur Cancer Therapy Centre Kinghorn Cancer Centre Chair, Upper GI working party AGITG APGI 18 June 2016. CANCER PROGRAM.

352 views • 18 slides

Case presented by Dr Schwartz

Case presented by Dr Schwartz. 44 yo woman with 4 mo hx of abdominal pain Imaging = pancreatic mass in body/tail 9/1/10: Distal pancreatectomy = well-circumscribed 6 cm adeno CA with perineural invasion, no nodes, but 4mm liver lesion ? mets

315 views • 14 slides

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer

63 views • 1 slides